Axel J Hueber
Overview
Explore the profile of Axel J Hueber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yalcin Mutlu M, Kleyer A, Kroenke G, Fagni F, Temiz S, Meder C, et al.
BMJ Open
. 2025 Jan;
15(1):e088486.
PMID: 39773803
Objectives: Although patients with immune-mediated inflammatory diseases (IMID) are thought to be more susceptible to viral infections, it is unclear whether their presentation differs between patients with IMID and healthy...
2.
Standfest K, Bartsch V, Beckert M, Hueber A
Z Rheumatol
. 2024 Mar;
83(7):575-577.
PMID: 38499768
No abstract available.
3.
Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, et al.
Lancet
. 2024 Feb;
403(10429):850-859.
PMID: 38364841
Background: Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain...
4.
Tascilar K, Hagen M, Kleyer A, Simon D, Reiser M, Hueber A, et al.
Lancet Rheumatol
. 2024 Feb;
3(11):e767-e777.
PMID: 38297524
Background: Owing to increasing remission rates, the management of patients with rheumatoid arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing Remission (RETRO) study investigated tapering...
5.
Fagni F, Yalcin Mutlu M, Temiz S, Minopoulou I, Krieter M, Schett G, et al.
RMD Open
. 2023 Dec;
9(4).
PMID: 38053458
Objectives: To assess the impact of low to moderate biomechanical stress on entheses in patients with psoriasis and psoriatic arthritis (PsA). Methods: We conducted a prospective interventional study on a...
6.
Watson L, Coyle C, Whately-Smith C, Brooke M, Kiltz U, Lubrano E, et al.
Rheumatology (Oxford)
. 2023 Nov;
63(12):3449-3456.
PMID: 38011669
Objectives: Shared decision-making (SDM) is advocated to improve patient outcomes in PsA. We analysed current prescribing practices and the extent of SDM in PsA across Europe. Methods: The ASSIST study...
7.
Bartsch V, Fagni F, Krieter M, Ibrahim M, Temiz S, Yalcin-Mutlu M, et al.
Rheumatology (Oxford)
. 2023 Nov;
63(11):e294-e296.
PMID: 37935433
No abstract available.
8.
Pfeil A, Klemm P, Hueber A, Hoffmann T, Weise T, Oelzner P, et al.
Rheumatology (Oxford)
. 2023 Sep;
63(7):1949-1956.
PMID: 37740288
Objective: The possibility of combining real and virtual environments is driving the increased use of augmented reality (AR) in education, including medical training. The aim of this multicentre study was...
9.
Werner S, Baraliakos X, Reckert S, Bohl-Buhler M, Laliberte M, Girard T, et al.
Rheumatol Ther
. 2023 Sep;
10(6):1503-1518.
PMID: 37695506
Introduction: Our aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic arthritis (PsA) using routine clinical practice data from...
10.
Stephan M, Tascilar K, Yalcin-Mutlu M, Hagen M, Haschka J, Reiser M, et al.
J Clin Med
. 2023 Jun;
12(11).
PMID: 37297917
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in...